Tetra Bio-Pharma (TBP.T) announced today that the Central Ethics Committee has approved the proposed protocol modifications allowing additional immediate release oral opioids to be used as a comparator in the REBORN1© study. Expanding to three immediate release oral opioids will allow for the acceleration of patient enrolment in the trial.
Latest News
Digital Twinning, and how EdgeTI (CTRL.V) is a serious story you’ve never heard of
Bionxt Solutions (BNXT.C): Seeking to confirm national-level cancer drug patent
Why Prospera Energy (PEI.V) might be a transformational investment opportunity in Canadian oil & gas
Sparc AI (SPAI.C) completes development of drone advanced target acquisition system
Plurilock (PLUR.V) lands $19 million deal, largest in their history
Rex Resources (OWN.V) continues gearing up with BC gold property